Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) has announced key near-term milestones in a new Innovators with Jane King interview with CEO Lisa Conte. The company is focusing on two main activities:

1. Planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair® in the U.S.

2. Progressing rare disease development with multiple investigator-initiated proof-of-concept studies for crofelemer in microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Results are expected by the end of 2024 and throughout 2025.

Jaguar also plans to enroll first patients for two global phase 2 studies for MVID and SBS-IF in Q4 2024. The company is continuing analysis of its pivotal phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea, with a focus on breast and lung cancer patients.

Jaguar Health (NASDAQ:JAGX) announced that Jordan's Industrial Property Protection Directorate has issued a new patent to Napo Pharmaceuticals for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar's intellectual property protection for its core rare disease target indication of SBS.

Jaguar is supporting independent investigator-initiated proof-of-concept studies for crofelemer in SBS and microvillus inclusion disease (MVID) across the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. These studies could potentially support early patient access to crofelemer in specific EU countries.

Napo currently holds approximately 173 patents and 60 patents pending. Crofelemer is the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance, providing additional exclusivity advantages.

Jaguar Health (NASDAQ:JAGX) announced that Dr. Eduardo Zimmer, a key collaborator with their joint venture Magdalena Biosciences, has received the prestigious Blas Frangione Early Career Achievement Award for 2024. This award recognizes early career researchers in Alzheimer's and dementia research. Magdalena, approximately 40% owned by Jaguar, is focused on developing novel, natural prescription psychoactive medicines from plants for mental health indications.

Magdalena recently initiated preclinical studies in Brazil to evaluate two botanical drug candidates for treating depression, anxiety, ADHD, and other neuropsychiatric conditions in adults. These studies use FDG PET scans to assess differential neuronal activity, with analysis performed by Dr. Zimmer's consultancy. The research aims to determine optimal dosing and therapeutic indications for potential future FDA approval as botanical drugs.

Jaguar Health (NASDAQ:JAGX) announced that Hong Kong's Intellectual Property Department has issued a new patent to Napo Pharmaceuticals, a Jaguar family company, for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar's IP protection for its core rare disease target indication of SBS.

Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease (MVID) in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. These studies could potentially support early patient access to crofelemer in specific EU countries.

Napo currently holds approximately 172 patents and 61 patents pending. Crofelemer is the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance, providing additional exclusivity advantages.

Jaguar Health has reported its Q2 2024 financial results, highlighting a 16% increase in combined net revenue to $2.72 million compared to Q1 2024. The revenue also saw a 2% growth compared to Q2 2023. Jaguar noted a decrease in various expenses and a significant decrease in net loss attributable to shareholders by 28% from $12.1 million in Q2 2023 to $9.5 million in Q2 2024. The company is set to launch its third prescription product, Gelclair, in October 2024 and is conducting pivotal phase 3 OnTarget trials of crofelemer for cancer therapy-related diarrhea. Additionally, an import permit for crofelemer was granted for trials in Abu Dhabi for pediatric patients with microvillus inclusion disease and short bowel syndrome.

The company will host an investor webcast on August 13, 2024, to discuss these updates.

Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast on August 13, 2024, at 8:30 AM Eastern Time. The webcast will cover Q2 2024 financial results and provide updates on the Phase 3 OnTarget trial, which showed clinically meaningful results for breast and lung cancer patients. Jaguar plans to explore approval pathways for crofelemer in these cancer types based on the trial outcomes. The company will file its Q2 2024 Earnings Report on Form 10-Q on the same day. Investors can register for the webcast through a provided link, and a replay will be available on Jaguar's website afterward.

Jaguar Health (NASDAQ:JAGX) has announced plans to explore an approval pathway for crofelemer in breast and lung cancer based on Phase 3 OnTarget trial results. The company will host a webcast on August 13, 2024, to review Q2 earnings and discuss the trial's clinically meaningful results. Key highlights include:

1. Crofelemer showed promising results for cancer therapy-related diarrhea (CTD) in breast and lung cancer patients.
2. An import permit was granted for a proof-of-concept trial of crofelemer in pediatric patients with rare diseases in Abu Dhabi.
3. Two independent studies on crofelemer for IBS-D have been accepted for presentation at a scientific meeting.
4. Jaguar is pursuing development for rare and orphan diseases, including MVID and SBS.
5. The company is also exploring plant-based medicines for mental health disorders through its Entheogen Therapeutics Initiative.

Jaguar Health (NASDAQ:JAGX) announced that Dr. Elaine Elisabetsky, a member of their Mental Health Entheogen Therapeutics Initiative, will speak at the University of Illinois Chicago College of Pharmacy on August 2, 2024. Her talk will cover decades of research on plant-based medicines for managing schizophrenia.

Dr. Elisabetsky is also an advisor to Magdalena Biosciences, a joint venture between Jaguar and Filament Health. Jaguar recently out-licensed a botanical drug candidate for schizophrenia and psychoses to Magdalena Biosciences. This candidate, sourced from a medicinal plant with traditional use, shows antipsychotic activity with a unique mechanism of action.

The global schizophrenia treatment market, valued at $8.29 billion in 2024, is projected to reach $13.41 billion by 2032. Schizophrenia affects about 1% of the U.S. population, with up to 34% of patients not responding to current treatments.

Jaguar Health (NASDAQ:JAGX) announced positive results from two investigator-initiated studies of crofelemer, its plant-based oral drug, for chronic refractory diarrhea in IBS-D patients. The data will be presented at the American College of Gastroenterology Annual Scientific Meeting in October 2024. Key findings include:

1. In functional diarrhea: Crofelemer significantly decreased stool consistency and abdominal pain without major side effects in a small crossover study of 18 patients.

2. In chronic idiopathic diarrhea: Nearly 60% of patients showed improvement within a 4-week treatment period.

These results suggest crofelemer's potential efficacy in treating subgroups of IBS-D, addressing an unmet need in gastroenterology. The company plans to continue investigating crofelemer for IBS-D management.